Suppr超能文献

多发性硬化症管理中的选择导航

Navigating choice in multiple sclerosis management.

作者信息

Linker Ralf A, Chan Andrew

机构信息

Department of Neurology, University of Regensburg, Universitätsstr. 84, 93053 Regensburg, Germany.

Ambulantes Neurozentrum, Inselspital, Bern University Hospital, Freiburgstr. 4, 3010 Bern, Switzerland.

出版信息

Neurol Res Pract. 2019 Feb 28;1:5. doi: 10.1186/s42466-019-0005-5. eCollection 2019.

Abstract

BACKGROUND

With the advent of modern immunotherapies for relapsing-remitting multiple sclerosis (RRMS) and the increasing amount of treatment options on the market, MS has evolved as a treatable disease. Yet, at the same time, new challenges for the treating neurologists arise.

MAIN BODY

This review article covers some of these challenges, including when and how to start treatment, treatment monitoring, and finally considerations on what the increasing choice in treatment options brings to disease management and longer-term planning. Among others, these important issues comprise pregnancy, treatment sequencing, switching or even stopping treatment.

CONCLUSION

The ultimate goal for navigating choices in RRMS management is to choose the right drug for the right patient at the right time Throughout the article, there is a strong focus on practical aspects and individual decision making in MS to meet the concept of personalized medicine.

摘要

背景

随着用于复发缓解型多发性硬化症(RRMS)的现代免疫疗法的出现以及市场上治疗选择的不断增加,多发性硬化症已发展成为一种可治疗的疾病。然而,与此同时,治疗神经科医生也面临着新的挑战。

正文

这篇综述文章涵盖了其中一些挑战,包括何时以及如何开始治疗、治疗监测,最后是关于治疗选择的增加给疾病管理和长期规划带来了什么的考量。其中,这些重要问题包括妊娠、治疗顺序、换药甚至停药。

结论

在RRMS管理中做出选择的最终目标是在正确的时间为正确的患者选择正确的药物。在整篇文章中,重点强烈放在多发性硬化症的实际方面和个体决策上,以符合个性化医疗的概念。

相似文献

1
Navigating choice in multiple sclerosis management.
Neurol Res Pract. 2019 Feb 28;1:5. doi: 10.1186/s42466-019-0005-5. eCollection 2019.
2
Survey of diagnostic and treatment practices for multiple sclerosis in Europe.
Eur J Neurol. 2017 Mar;24(3):516-522. doi: 10.1111/ene.13236. Epub 2017 Jan 31.
3
Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
BMC Med Res Methodol. 2020 Feb 7;20(1):24. doi: 10.1186/s12874-020-0906-6.
4
Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.
Curr Med Res Opin. 2018 Aug;34(8):1419-1430. doi: 10.1080/03007995.2018.1458023. Epub 2018 Apr 18.
5
Rituximab for relapsing-remitting multiple sclerosis.
Cochrane Database Syst Rev. 2013 Dec 6;2013(12):CD009130. doi: 10.1002/14651858.CD009130.pub3.
6
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.
Neuropsychiatr Dis Treat. 2013;9:893-914. doi: 10.2147/NDT.S45144. Epub 2013 Jun 24.
7
Patient and neurologist preferences in the UK for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment.
Curr Med Res Opin. 2021 Sep;37(9):1589-1598. doi: 10.1080/03007995.2021.1940911. Epub 2021 Jul 8.
9
Established disease-modifying treatments in relapsing-remitting multiple sclerosis.
Curr Opin Neurol. 2015 Jun;28(3):220-9. doi: 10.1097/WCO.0000000000000202.

引用本文的文献

1
The Role of Cobalamin in Multiple Sclerosis: An Update.
Inflammation. 2025 Apr;48(2):485-500. doi: 10.1007/s10753-024-02075-6. Epub 2024 Jun 21.
2
Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?
Curr Neuropharmacol. 2024;22(8):1286-1326. doi: 10.2174/1570159X22666240124114126.
3
Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS) (ConPlanEM Study): Delphi Consensus Statements.
Cureus. 2023 Aug 24;15(8):e44056. doi: 10.7759/cureus.44056. eCollection 2023 Aug.
5
Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment.
Mult Scler J Exp Transl Clin. 2023 Jan 23;9(1):20552173221150370. doi: 10.1177/20552173221150370. eCollection 2023 Jan-Mar.
6
Ontology for Symptomatic Treatment of Multiple Sclerosis.
Healthc Inform Res. 2022 Oct;28(4):332-342. doi: 10.4258/hir.2022.28.4.332. Epub 2022 Oct 31.
7
Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain.
PLoS One. 2021 Dec 8;16(12):e0261050. doi: 10.1371/journal.pone.0261050. eCollection 2021.
8
Neurological research and practice: the first year.
Neurol Res Pract. 2020 Feb 28;2:5. doi: 10.1186/s42466-020-0054-9. eCollection 2020.
9
Expert opinion on the use of cladribine tablets in clinical practice.
Ther Adv Neurol Disord. 2020 Jun 24;13:1756286420935019. doi: 10.1177/1756286420935019. eCollection 2020.

本文引用的文献

1
Neurofilaments as biomarkers in neurological disorders.
Nat Rev Neurol. 2018 Oct;14(10):577-589. doi: 10.1038/s41582-018-0058-z.
2
A case of immune-mediated encephalitis related to daclizumab therapy.
Mult Scler. 2019 Apr;25(5):750-753. doi: 10.1177/1352458518792403. Epub 2018 Aug 3.
3
GFAPα IgG-associated encephalitis upon daclizumab treatment of MS.
Neurol Neuroimmunol Neuroinflamm. 2018 Jul 13;5(5):e481. doi: 10.1212/NXI.0000000000000481. eCollection 2018 Sep.
4
Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS.
Neurol Neuroimmunol Neuroinflamm. 2018 Jul 10;5(5):e479. doi: 10.1212/NXI.0000000000000479. eCollection 2018 Sep.
5
Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy.
Neurology. 2018 Jul 24;91(4):e359-e363. doi: 10.1212/WNL.0000000000005854. Epub 2018 Jun 22.
6
Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm.
Curr Opin Neurol. 2018 Jun;31(3):233-243. doi: 10.1097/WCO.0000000000000561.
7
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.
CNS Drugs. 2018 Mar;32(3):269-287. doi: 10.1007/s40263-018-0488-6.
8
Multicenter reliability of semiautomatic retinal layer segmentation using OCT.
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 13;5(3):e449. doi: 10.1212/NXI.0000000000000449. eCollection 2018 May.
9
A Fully Automated Pipeline for Normative Atrophy in Patients with Neurodegenerative Disease.
Front Neurol. 2018 Jan 24;8:727. doi: 10.3389/fneur.2017.00727. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验